René Laennec invented the stethoscope in 1816 because he was uncomfortable placing his ear directly on a young woman’s chest. Werner Forssmann performed the first cardiac catheterization, on himself, in 1929, threading a catheter through his own arm into his heart because no ethics board would have approved it on a patient. Graeme Clark developed the cochlear implant after watching his deaf father struggle to communicate. Charles Kelman revolutionized cataract surgery by adapting the ultrasonic technology he’d observed in his dentist’s office.

Every one of these breakthroughs came from a physician who encountered a clinical problem, refused to accept it as permanent, and built the solution. For most of medical history, physician and innovator were not separate identities. They were the same person.

Somewhere along the way, we stopped.

The shift nobody talks about

Over the past three decades, health care innovation has undergone a quiet transformation. The physician-inventor has been replaced by the non-clinical founder. The clinical insight that used to drive product development now comes secondhand, filtered through consultant interviews and customer discovery calls conducted by people who have never held a scalpel or managed a ventilator.

This shift wasn’t malicious. It was structural. As health care became more complex, the infrastructure required to build a company (regulatory navigation, fundraising, manufacturing, commercialization) grew beyond what any individual physician could manage while maintaining a clinical practice. At the same time, venture capital discovered health care as an asset class. Capital flooded in. But it came with its own logic: Build fast, scale fast, exit fast. The pace of modern startup culture is fundamentally incompatible with the careful, evidence-based methodology physicians are trained to apply.

So physicians stepped back. We became the end users of innovations designed by others rather than the architects of those innovations ourselves. We evaluate products someone else built. We adopt technology someone else funded. We live with workflow changes someone else decided we needed.

And the results speak for themselves. Billions of dollars are invested every year in health care products that fail, not because the technology doesn’t work, but because the people who built them never fully understood the clinical problem they were trying to solve.

What we lost

When physicians stopped being innovators, health care lost something that no amount of venture capital can replace: the direct line between clinical frustration and product creation.

Laennec didn’t need a market research report to know that auscultation was limited. Forssmann didn’t run a focus group before catheterizing his own heart. Clark didn’t hire a consulting firm to validate the need for hearing restoration. They saw problems. They built solutions. The validation was embedded in the invention because the inventor was also the clinician.

Today, that direct line is broken. A non-clinical founder identifies a problem through interviews and research, which is a valid approach, but it introduces a translation layer that inevitably loses fidelity. The physician who lives inside the workflow every day sees nuances that no interview can capture: the workaround that makes an existing solution good enough, the adoption barrier that exists in culture rather than technology, the regulatory reality that makes a promising product commercially unviable.

When that insight is filtered through a non-clinical team, the highest-resolution signal in health care, physician experience at the point of care, gets compressed into a pitch deck that may or may not reflect clinical reality.

The reclaiming has already started

The encouraging reality is that physicians haven’t entirely stopped innovating. They’ve just been doing it quietly, without much infrastructure or recognition.

Physician-founded companies are emerging across digital health, biotech, medical devices, and therapeutics. Many of the most clinically grounded health care startups I’ve evaluated were built by physicians who saw a problem during residency or clinical practice and decided to solve it, often without any formal training in entrepreneurship, fundraising, or company building.

What these physician-founders share is the same quality that defined Laennec and Forssmann: They refused to accept that the clinical problem they encountered every day was someone else’s job to fix. They recognized that their proximity to the problem wasn’t just clinically valuable, it was the most important competitive advantage a health care company could have.

As a physician-scientist who transitioned into health care venture capital, I’ve made it a priority to find and fund these physician-led companies. Over 20 investments, the pattern is consistent: The strongest health care startups are the ones where someone on the founding team has personally experienced the problem the company is solving. Not studied it. Not researched it. Lived it.

What needs to change

The path back to physician-led innovation doesn’t require every doctor to become a startup founder. It requires three things.

First, exposure. As of 2016, only 13 medical schools offered any form of entrepreneurship programming. Most residents graduate without ever learning that building a company around a clinical insight is a viable career path, or even a viable side project. Simply showing physicians that this pathway exists would unlock an enormous amount of dormant innovation.

Second, infrastructure. Physician-founders need access to regulatory expertise, reimbursement strategy, fundraising networks, and operational support that most clinicians don’t have. The physician-led funds and innovation programs that are beginning to emerge, including physician networks that provide clinical diligence and distribution support to portfolio companies, are starting to fill this gap.

Third, capital that values clinical insight. The current venture capital model evaluates health care companies primarily through financial metrics: total addressable market, revenue growth, unit economics. These matter. But they’re insufficient without an equally rigorous evaluation of clinical necessity, adoption feasibility, and evidence quality. When capital is allocated by people who understand clinical reality, better companies get funded.

The stethoscope was invented by a physician who saw a problem and refused to accept it

Two hundred years later, the health care industry is a $5.3 trillion ecosystem with over $140 billion in annual private capital investment. The problems are bigger, the solutions are more complex, and the stakes are higher than anything Laennec could have imagined.

But the fundamental dynamic hasn’t changed. The people who understand health care problems most deeply are the people who live inside them every day. For two centuries, those people, physicians, drove health care innovation forward. The fact that we’ve stepped back from that role over the past few decades is not inevitable. It’s a correctable mistake.

The tools, the capital, and the infrastructure are more accessible than they’ve ever been. The question is whether physicians will pick them up.

We’ve done it before. We can do it again.

Harsha Moole is an internal medicine-trained physician-scientist with more than 100 peer-reviewed publications, including work featured in the New England Journal of Medicine. After years of clinical practice and gastroenterology outcomes research, he made an unconventional transition from the bedside to the boardroom by founding PhysicianEstate, a health care-focused venture capital firm.

Over the past seven years, Dr. Moole has made 22 early-stage health care investments across digital health, medical devices, biotech, and therapeutics. He has also built a network of more than 200 physicians from institutions such as Johns Hopkins and Stanford who help source opportunities and provide clinical diligence before capital is deployed. His core thesis is that physician-scientists with firsthand clinical experience are uniquely positioned to identify health care investments that generalist investors often miss.

His research background is reflected in his publication record on Google Scholar, and he shares professional updates on LinkedIn.